The main purpose of this study is to determine the safety of LY2409021 in healthy participants and participants with diabetes. The study drug is given as single oral doses. Each participant can receive up to 3 doses, with a minimum 7 day washout between dosing periods. Side effects will be documented. This study is approximately 9 weeks long, not including screening. Screening is required within 6 weeks prior to the start of the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
32
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Singapore, Singapore
Number of participants with one or more drug related adverse events (AEs) or any serious AEs
Time frame: From first dose of study drug up to discharge (at least 14 days after last dose)
Pharmacokinetics: Area under the concentration curve (AUC) of LY2409021
Time frame: From each dose of study drug up to 14 days post dose
Pharmacokinetics: Maximum concentration (Cmax) of LY2409021
Time frame: From each dose of study drug up to 14 days post dose
Change in fasting blood glucose level
Time frame: From each dose of study drug up to 48 hours post dose
Change in fasting insulin level
Time frame: From each dose of study drug up to 48 hours post dose
Change in fasting glucagon level
Time frame: From each dose of study drug up to 48 hours post dose
Change in fasting glucagon-like peptide-1 (GLP-1) level
Time frame: From each dose of study drug up to 24 hours post dose
Glucose excursion after meals
Time frame: 28 hours after each dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.